Earlier this year, the Amador team had the incredible opportunity to engage in a dynamic discussion with the NYSE Cassandra Seier, Head of International Capital Markets and Johanna Grossman, PhD, Head of Healthcare & Life Sciences Capital Markets teams at the historic NYSE building.
Our delegation included Xiaomin Chen, MBA, COO, Meina Liang, Ph.D, CTO, and Sophia Cao, the secretary of the board.
The conversation was nothing short of inspiring, as we delved into the ever-evolving global biotechnology landscape. Topics ranged from fostering tighter collaborations between multinational corporations and innovative Chinese biotech companies to the indispensable role of translational science in enhancing the efficiency of clinical development.
Amador's unique positioning in the US, Europe, and Chinese markets, coupled with our laser focus on model and biomarker informed drug development, places us at the forefront of these progresses. The NYSE teams recognized the immense potential for Amador to make significant contributions and seize the opportunities that lie ahead.